论文部分内容阅读
目的:观察美罗华联合CHOP方案治疗非霍奇金淋巴瘤的疗效,总结不良反应及相应处理措施。方法:采用美罗华联合CHOP方案治疗15例CD20阳性的非霍奇金淋巴瘤患者,观察疗效和他们在治疗期间的不良反应,并提出相应的处理措施。结果:根据血液病诊断及疗效标准[4],本组15例有8例完全缓解、5例部分缓解、2例未缓解(病情稳定)。首次输注美罗华的患者出现以下不良反应:高热2例,喉头发痒1例,骨髓抑制9例,恶心、呕吐11例。结论:美罗华联合CHOP方案疗效较为理想,并未增加毒性,所出现的不良反应可以通过对应治疗提高患者耐受性。
Objective: To observe the curative effect of rituximab combined with CHOP regimen in the treatment of non-Hodgkin’s lymphoma and to summarize the adverse reactions and the corresponding treatment measures. METHODS: Fifteen patients with CD20 positive non-Hodgkin’s lymphoma were treated with rituximab and CHOP regimen. The curative effect and their adverse reactions during treatment were observed and corresponding treatment measures were proposed. Results: According to the diagnosis and efficacy of blood disease standard [4], 15 patients in this group, 8 patients were completely relieved, 5 patients partially relieved, 2 patients did not relieve (stable condition). In the first infusion of rituximab, patients developed the following adverse reactions: fever in 2 cases, throat itchy in 1 case, bone marrow suppression in 9 cases, and nausea and vomiting in 11 cases. Conclusion: The combination of rituximab and CHOP is more effective and does not increase the toxicity. The adverse reactions can be improved by corresponding treatment.